Metis TechBio Co., Ltd. (7666.HK) is mainly engaged in AI-empowered nanomaterial innovation, dedicated to the delivery and application of functional payloads across lifeforms, and drug designed using AI-driven formulation technology.

Our team has provided the following services to the company:
- Independent internal control review service for IPO